Abstract: The invention relates to methods and kits for determining and optimizing a personalized treatment regimen for a subject suffering from a pathologic disorder based on calculating the value of M, that indicates the ability of said subject to eliminate said disorder. The invention specifically relates to optimization of interferon treatment of viral disorders.

Abstract: Methods and kits for predicting the response of a subject to an anti-TNF? therapy, in high accuracy, are provided.

Abstract: The invention relates to methods and kits for determining and optimizing a personalized treatment regimen for a subject suffering from a pathologic disorder based on calculating the value of M, that indicates the ability of said subject to eliminate said disorder. The invention specifically relates to optimization of interferon treatment of viral disorders.

Abstract: Methods and kits for the diagnosis of cancer based on specific expression profiles of Cancer Testis Antigens (CTA) are provided.

Abstract: The present invention relates to methods and kits for the prediction and diagnosis of intrauterine-transmission of viral pathogens, specifically, hCMV in a mammalian subject, by calculating the ability of a subject to prevent transmission of said hCMV based on determining the expression of ISG15, IFIT3 and USP18 genes and optionally of EIF2AK2, HERC5, RSAD2 and MX1 genes in a sample of said subject.

Abstract: The invention relates to methods and kits for determining and optimizing a personalized treatment regimen for a subject suffering from a pathologic disorder based on calculating the value of M, that indicates the ability of said subject to eliminate said disorder. The invention specifically relates to optimization of interferon treatment of viral disorders.

Abstract: The present invention relates to kits, arrays, compositions and methods for predicting, assessing and evaluating responsiveness and success of interferon treatment as well as for monitoring disease progression and pathophysiology in a subject treated with interferon, using OAS2, HERC5, UPS18, UBE2L6 and optionally of ISG15 genes as biomarkers.

Abstract: The invention relates to methods and kits for determining and optimizing a personalized treatment regimen for a subject suffering from a pathologic disorder, specifically, MS, based on the expression pattern of specific marker genes.

Abstract: The present invention relates to methods, compositions and kits for predicting, assessing and evaluating responsiveness and success of interferon treatment as well as methods for monitoring disease progression and pathophysiology in a subject treated with interferon, using miR-146a and optionally at least one of miR-146a regulated genes as biomarkers.

Abstract: A computerized method and system for detection and quantification of changes in color on skin or internal tissue or organs within the human body. Digital images of the skin or tissue containing an area of interest are analyzed using the software of the invention, based on at least one channel of the LAB color system. The invention calculates the intensity and distribution of color present within the predetermined area of interest, and results in display of at least one color information attribute. The invention allows color calibration of the image to be performed in relation to a reference label having predetermined colors which surrounds the area of interest, prior to the analysis. The invention allows a threshold analysis to be performed, which graphically depicts the size and location of areas exhibiting significant change in color, which is a determinant factor in medical diagnosis.

Abstract: The invention provides a method for selecting one or more genes from among a predetermined group of genes whose expression level is significantly different among a first group of individuals in a population in comparison with a second group within the population. The first group of individuals may be, a group of individuals suffering from an illness that responded to a predetermined treatment. The second group of individuals may be a group of individuals suffering from the same illness that did not respond to the treatment.

Abstract: A method for classifying a test tissue sample into a class from among K classes, where the test tissue sample has an associated gene expression vector is provided. For each class k from among the K classes, a gene expression matrix is provided based upon a gene expression level in one or more tissue samples known to be in the class k. One or more eigenvectors of the covariance matrix Cx of the centralized gene expression matrix are calculated. A metric ?k that is indicative of the extent of dissimilarity between the gene expression vector and the gene expression matrix is calculated using an algebraic expression involving one or more of the eigenvectors of the matrix Cx. The test tissue sample is then classified into a class k for which the metric ?k is minimum among the k classes.

Abstract: Provided are methods of predicting responsiveness of a subject to interferon treatment, comprising comparing a level of expression in a cell of the subject of at least one gene selected from the group consisting KIR3DL3, KIR3DL2, KIR3DL1, KIR2DL1, KIR2DL2, KIR2DL3, KLRG1, KIR3DS1, CD160, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G and IFI27 to a reference expression data of the at least one gene obtained from at least one interferon responder subject and/or at least one interferon non-responder subject. Also provided are methods and pharmaceutical compositions for treating a subject in need of interferon treatment.

Abstract: The invention provides a method for selecting one or more genes from among a predetermined group of genes whose expression level is significantly different among a first group of individuals in a population in comparison with a second group within the population. The first group of individuals may be, for example, a group of individuals suffering from an illness that responded to a predetermined treatment. The second group of individuals may be a group of individuals suffering from the same illness that did not respond to the treatment.

Abstract: A computerized method and system for detection and quantification of changes in color on skin or internal tissue or organs within the human body. Digital images of the skin or tissue containing an area of interest are analyzed using the software of the invention, based on at least one channel of the LAB color system. The invention calculates the intensity and distribution of color present within the predetermined area of interest, and results in display of at least one color information attribute. The invention allows color calibration of the image to be performed in relation to a reference label having predetermined colors which surrounds the area of interest, prior to the analysis. The invention allows a threshold analysis to be performed, which graphically depicts the size and location of areas exhibiting significant change in color, which is a determinant factor in medical diagnosis.

Abstract: A method for classifying a test tissue sample into a class from among K classes, where the test tissue sample has an associated gene expression vector is provided. For each class k from among the K classes, a gene expression matrix is provided based upon a gene expression level in one or more tissue samples known to be in the class k. One or more eigenvectors of the covariance matrix Cx of the centralized gene expression matrix are calculated. A metric ?k that is indicative of the extent of dissimilarity between the gene expression vector and the gene expression matrix is calculated using an algebraic expression involving one or more of the eigenvectors of the matrix Cx. The test tissue sample is then classified into a class k for which the metric ?k is minimum among the k classes.

Abstract: A similarity measurement method for the classification of medical images into predetermined categories. A small set of pre-classified images is required to employ the method. The images can be real world images acquired using a camera, computer tomography, etc., or schematic drawings representing samples of different classes. The use of schematic drawings as a source of images allows a quick test of the method for a particular classification problem. The eigenvectors for each category are mathematically derived, and each image in each category is represented as a weighted linear combination of the eigenvectors. A test image is provided and projected onto the eigenvectors of each of the categories so as to reconstruct the test image with the eigenvectors. The RMS (root-mean-square) distance between the test image and each of the categories is measured.